<DOC>
	<DOCNO>NCT00701779</DOCNO>
	<brief_summary>This study investigate efficacy safety treatment Dutasteride ( 0.5mg ) , administer daily one year combination Tamsulosin ( 0.4mg ) , administer daily 3 month , follow counsel flexible dose Tamsulosin need basis , improvement symptom clinical outcome men moderate severe symptomatic benign prostatic hyperplasia ( BPH ) . At scheduled visit ( 3 , 6 , 9 month ) , subject counsel withdrawal Tamsulosin . After randomization , study visit every 13 week 52 Weeks . ( Including Screening , ( 7 clinic visit )</brief_summary>
	<brief_title>Dutasteride Flex Dose Tamsulosin Needed Basis , Treat Benign Prostatic Hyperplasia</brief_title>
	<detailed_description>This study investigate efficacy safety treatment Dutasteride ( 0.5mg ) , administer daily one year combination Tamsulosin ( 0.4mg ) , administer daily 3 month , follow counsel flexible dose Tamsulosin need basis , improvement symptom clinical outcome men moderate severe symptomatic benign prostatic hyperplasia ( BPH ) . At scheduled visit ( 3 , 6 , 9 month ) , subject counsel withdrawal Tamsulosin . A recently publish , landmark study ( MTOPS - Medical Therapy Prostatic Symptoms ) , co-sponsored National Institute Health National Institute Diabetes , Digestive Kidney Diseases ( NIH-NIDDK ) , demonstrate , select patient , combination therapy Doxazosin Finasteride provide additive symptomatic improvement , reduce risk acute urinary retention ( AUR ) surgical intervention , effective treatment reduction overall risk BPH clinical progression . The aim propose combination study , population patient high risk BPH clinical progression , investigate whether combination therapy Dutasteride Tamsulosin subsequent withdrawal Tamsulosin maintain superior symptom improvement . At scheduled visit ( 3 , 6 , 9 month ) , subject counsel withdrawal Tamsulosin . We hypothesize patient may start combination Dutasteride Tamsulosin eventually may able eliminate use Tamsulosin maintain acceptable urinary symptom Dutasteride alone .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>1 . Male ≥50 yr 2 . Diagnosed BPH medical history physical examination , include digital rectal examination 3. International Prostate Symptom Score ≥12 point Screening 4 . Prostate volume ≥30cc ( transrectal ultrasonography ; TRUS ) 5 . Total serum Prostate Specific Antigen ≥1.5 ng/mL Screening 6 . Maximum flow rate ≥5 mL/sec ≤15 mL/sec minimum void volume ≥125 mL Screening ( base two void ) 7 . Able give write informed consent comply study procedures 8 . Literate English language ability read , comprehend , record information IPSS , BII , PPSM questionnaires 9 . Able swallow retain oral medication 10 . Able participate study duration 1 . Total serum PSA &gt; 10.0 ng/mL Screening . Patients total serum PSA &gt; 10.0 ng/mL may acceptable inclusion PSA elevation think due BPH prostate cancer ( TRUS biopsies show evidence prostate cancer ) . 2 . History evidence prostate cancer 3 . Previous prostatic surgery invasive procedure treat BPH 4 . History flexible/rigid cystoscopy instrumentation urethra within 7 day prior Screening . Catheterization ( &lt; 10F ) acceptable time restriction . 5 . History AUR within 3 month prior Screening 6 . Postvoid residual volume &gt; 250mL ( suprapubic ultrasound ) Screening 7 . Any cause BPH , may judgment investigator , result urinary symptom change flow rate 8 . History breast cancer clinical breast examination find unclear origin suggestive malignancy 9 . Use 5 alphareductase inhibitor , drug antiandrogenic property , drug note gynecomastia effect , within past 6 month throughout study . Previous use AVODART within 12 month baseline historical TRUS . Chronic use Metronidazole prohibit . 10 . Concurrent use anabolic steroid 11 . Use phytotherapy BPH within 2 week Screening 12 . Use alphaadrenoreceptor blocker within 2 week Screening 13 . Use alphaadrenoreceptor agonist , anticholinergic cholinergics within 48 hour prior uroflowmetry assessment . 14 . Hypersensitivity alpha/beta adrenoreceptor blocker 5alphareductase inhibitor , chemicallyrelated drug . 15 . Concurrent use drug know thought interaction Tamsulosin . 16 . History hepatic impairment , abnormal liver function Screening , History renal insufficiency , serum creatinine &gt; 1.5 time upper limit 18. history malignancy basal cell carcinoma squamous cell carcinoma skin within past 2 year . 19 . History illness investigator might confound result study pose additional risk patient . 20 . Any unstable , serious coexist medical condition ( ) 21 . History postural hypotension , dizziness , vertigo , sign symptom orthostasis . 22 . History 'first dose ' hypotensive episode initiation alphaladrenoreceptor antagonist therapy . 23 . History unsuccessful treatment finasteride Dutasteride 24 . History current drug alcohol abuse within previous 12 month . 25 . Participation investigational market drug trial within 30 day ( 5 halflives whichever longer ) precede Screening and/or course study .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>Dutasteride</keyword>
	<keyword>Tamsulosin</keyword>
</DOC>